Anika Therapeutics (ANIK) closed at $13.40 on November 13, 2026, down 3.0% from the previous close, on volume of 84,969 shares (30-day average 115,322).
Data as of November 13, 2026.
13-Nov-2026
Anika Therapeutics Earnings Call Signals Stronger Growth Ahead
TipRanks (Sat, 14-Nov 9:12 PM ET)
Anika Reports Third Quarter 2026 Financial Results
Globe Newswire (Fri, 6-Nov 7:05 AM ET)
Anika to Issue Third Quarter 2026 Financial Results on Friday, November 6, 2026
Globe Newswire (Thu, 22-Oct 4:01 PM ET)
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.
Anika Therapeutics trades on the NASDAQ stock market under the symbol ANIK.
As of November 13, 2026, ANIK stock price declined to $13.40 with 84,969 million shares trading.
ANIK has a beta of 1.02, meaning it tends to be more sensitive to market movements. ANIK has a correlation of 0.05 to the broad based SPY ETF.
ANIK has a market cap of $179.33 million. This is considered a Micro Cap stock.
Last quarter Anika Therapeutics reported $31 million in Revenue and $.29 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.15.
In the last 3 years, ANIK traded as high as $29.12 and as low as $7.87.
The top ETF exchange traded funds that ANIK belongs to (by Net Assets): VTI, IWM, VXF, DFSV, IWN.
ANIK has outperformed the market in the last year with a return of +32.7%, while the SPY ETF gained +13.4%. However, in the most recent history, ANIK shares have underperformed the stock market with its stock returning -36.7% in the last 3 month period and -36.0% for the last 2 week period, while SPY has returned -2.8% and -0.2%, respectively.
ANIK support price is $13.30 and resistance is $14.33 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ANIK shares will trade within this expected range on the day.
